BMJ Open Diabetes Research & Care,
Journal Year:
2024,
Volume and Issue:
12(4), P. e004291 - e004291
Published: Aug. 1, 2024
The
prevalence
of
type
2
diabetes
(T2D)
is
increasing
relentlessly
all
over
the
world,
in
parallel
with
a
similar
increase
obesity,
and
striking
ever
younger
patients.
Only
minority
patients
T2D
attain
glycemic
targets,
indicating
clear
need
for
novel
antidiabetic
drugs
that
not
only
control
glycemia
but
also
halt
or
slow
progressive
loss
β-cells.
Two
entirely
classes
agents—glucokinase
activators
imeglimin—have
recently
been
approved
will
be
subject
this
review.
Allosteric
glucokinase,
an
enzyme
stimulating
insulin
secretion
β-cells
suppressing
hepatic
glucose
production,
are
oral
low-molecular-weight
drugs.
One
these,
dorzagliatin,
China
use
adult
T2D,
either
as
monotherapy
add-on
to
metformin.
It
remains
seen
whether
drug
produce
sustained
effects
many
years
side
led
discontinuation
early
candidates
limit
usefulness
dorzagliatin.
Imeglimin—which
shares
structural
similarities
metformin—targets
mitochondrial
dysfunction
was
Japan
against
T2D.
In
preclinical
studies,
has
shown
promising
β-cell
protective
preservative
may
translate
into
disease-modifying
effects.
Hopefully,
these
two
newcomers
contribute
filling
great
medical
new
treatment
modalities,
preferably
potential.
where
they
fit
contemporary
algorithms,
which
combinations
effective
should
avoided.
Time
tell
what
extent
agents
add
value
current
options
terms
effect,
acceptable
safety,
utility
combination
therapy,
impact
on
hard
end-points
such
cardiovascular
disease.
Journal of Medical Internet Research,
Journal Year:
2025,
Volume and Issue:
27, P. e69466 - e69466
Published: Feb. 28, 2025
Background
Obesity
is
a
global
public
health
challenge.
Pharmacological
interventions,
such
as
glucagon-like
peptide-1
(GLP-1)
receptor
agonists
(eg,
semaglutide)
and
dual
GLP-1/gastric
inhibitory
polypeptide
tirzepatide),
have
led
to
significant
weight
loss
among
users.
Digital
platforms
offering
behavioral
support
may
enhance
the
effectiveness
of
these
medications.
Objective
This
retrospective
service
evaluation
investigated
impact
engagement
with
an
app-based
digital
program
on
outcomes
individuals
using
GLP-1
(semaglutide)
(tirzepatide)
in
United
Kingdom
over
5
months.
Methods
Data
were
collected
from
Voy
platform
between
February
2023
August
2024.
Participants
adults
aged
18-75
years
BMI
≥30
or
≥27.5
kg/m2
presence
obesity-related
comorbidities
who
initiated
management
involving
semaglutide
tirzepatide.
Engagement
was
defined
based
attendance
at
coaching
sessions,
frequency
app
use,
regular
tracking.
categorized
“engaged”
“nonengaged”
accordingly.
Weight
assessed
period
up
Statistical
analyses
included
chi-square
tests,
independent
t
Kaplan-Meier
survival
analysis,
calculations
Cohen
d
for
effect
sizes.
Results
A
total
57,975
participants
31,407
(54.2%)
classified
engaged
26,568
(45.8%)
nonengaged.
Engaged
achieved
significantly
greater
each
time
point.
At
month
3,
had
mean
9%
(95%
CI
9.1%)
compared
5.9%
6%)
nonengaged
(P<.001),
representing
difference
3.1
percentage
points
3.1%
3.1%).
size
0.89
indicated
large
effect.
5,
11.53%
11.5%
11.6%)
8%
7.9%
8%)
(P<.001).
0.56
moderate
tirzepatide
more
than
those
(13.9%,
95%
13.5%
14.3%
vs
9.5%,
9.2%
9.7%;
P<.001).
The
proportion
achieving
≥5%,
≥10%,
≥15%
higher
group
corresponding
months
3
respectively
Conclusions
enhances
agonists.
combination
pharmacotherapy
offers
promising
strategy
promote
supported
self-care
journey
seeking
clinically
effective
obesity
interventions.
Abstract
Incretin
mimetics,
also
known
as
glucagon-like
peptide-1
(GLP-1)
receptor
agonists,
are
a
class
of
medications
used
to
treat
type
2
diabetes
by
mimicking
the
actions
incretin
hormones
in
body.
These
responsible
for
promoting
insulin
release
from
pancreas
response
nutrient
intake,
well
decreasing
glucagon
secretion,
slowing
gastric
emptying,
and
satiety.
By
imitating
these
actions,
mimetics
help
regulate
blood
sugar
levels
individuals
with
glucose
intolerance.
One
key
benefits
is
its
ability
lower
without
causing
hypoglycemia.
This
especially
important
who
may
experience
dangerous
drops
when
using
other
medications.
Additionally,
have
been
shown
promote
weight
loss
some
individuals,
making
them
valuable
option
those
struggling
obesity
addition
diabetes.
administered
injection,
once
or
twice
daily,
depending
on
specific
medication.
They
often
combined
medications,
such
metformin
insulin,
optimal
control.
generally
well-tolerated,
common
side
effects
including
nausea,
vomiting,
diarrhea,
which
usually
diminish
over
time
body
adjusts
Studies
that
can
improve
cardiovascular
outcomes
diabetes,
reducing
risk
heart
attacks
strokes.
particularly
significant
given
increased
disease
preserve
pancreatic
beta-cell
function,
producing
insulin.
slow
progression
reduce
need
higher
doses
time.
Despite
their
many
benefits,
not
limitations.
be
expensive
compared
make
less
accessible
individuals.
there
concerns
about
potential
pancreatitis
cancer
associated
use
However,
more
research
needed
fully
understand
risks.
It
healthcare
providers
carefully
assess
each
individual's
unique
needs
medical
history
considering
mimetics.
appropriate
everyone,
cancer.
Patients
should
educated
medications'
proper
administration
ensure
safety
efficacy.
Overall,
emerged
an
therapeutic
offering
mechanism
action
control,
loss,
risk.
With
ongoing
development
this
field,
continue
show
promise
tools
managing
complications
comorbidities.
BMJ Open Diabetes Research & Care,
Journal Year:
2024,
Volume and Issue:
12(4), P. e004291 - e004291
Published: Aug. 1, 2024
The
prevalence
of
type
2
diabetes
(T2D)
is
increasing
relentlessly
all
over
the
world,
in
parallel
with
a
similar
increase
obesity,
and
striking
ever
younger
patients.
Only
minority
patients
T2D
attain
glycemic
targets,
indicating
clear
need
for
novel
antidiabetic
drugs
that
not
only
control
glycemia
but
also
halt
or
slow
progressive
loss
β-cells.
Two
entirely
classes
agents—glucokinase
activators
imeglimin—have
recently
been
approved
will
be
subject
this
review.
Allosteric
glucokinase,
an
enzyme
stimulating
insulin
secretion
β-cells
suppressing
hepatic
glucose
production,
are
oral
low-molecular-weight
drugs.
One
these,
dorzagliatin,
China
use
adult
T2D,
either
as
monotherapy
add-on
to
metformin.
It
remains
seen
whether
drug
produce
sustained
effects
many
years
side
led
discontinuation
early
candidates
limit
usefulness
dorzagliatin.
Imeglimin—which
shares
structural
similarities
metformin—targets
mitochondrial
dysfunction
was
Japan
against
T2D.
In
preclinical
studies,
has
shown
promising
β-cell
protective
preservative
may
translate
into
disease-modifying
effects.
Hopefully,
these
two
newcomers
contribute
filling
great
medical
new
treatment
modalities,
preferably
potential.
where
they
fit
contemporary
algorithms,
which
combinations
effective
should
avoided.
Time
tell
what
extent
agents
add
value
current
options
terms
effect,
acceptable
safety,
utility
combination
therapy,
impact
on
hard
end-points
such
cardiovascular
disease.
